USP and Public Policy

Left

USP Comment Letter: Submitted to US Hemp Authority Certification Program Standard (2020)

USP appreciates the opportunity to comment on the U.S. Hemp Authority Certification Program Standard v3.0 DRAFT. Learn More

USP Comment Letter: Submitted to HHS/ASPR/DSNS on Strategic National Stockpile (SNS) (2020)

USP appreciates the opportunity to provide comments in response to the request for information (RFI) from HHS/ASPR/DSNSS on the Strategic National Stockpile (SNS). Learn More

USP Comment Letter: Submitted to Health Canada on Cannabis Standards (2020)

USP appreciates the opportunity to on Health Canada's Controlled Substances and Cannabis Branch regarding quality issues of cannabis. Learn More

USP Comment Letter: Submitted to FDA on Fixed-Quantity Unit-of-Use Blister Packaging for Certain Immediate-Release Opioid Analgesics for Treatment of Acute Pain (2019)

USP appreciates the opportunity to respond to the U.S. Food and Drug Administration's (FDA's) Request for Comments on Fixed-Quantity Unit-of-Use Blister Packaging for Certain Immediate-… Learn More

USP Comment Letter: Submitted to FDA on Horizontal Approaches to Food Standards of Identity (SOI) Modernization (2019)

USP appreciates the opportunity to submit comments on the horizontal approaches to food standards of identity (SOI) modernization. These comments are being submitted on behalf of the Food Science… Learn More

USP Testimony: Submitted to FDA on Modernizing Standards of Identity (SOI) (2019)

USP appreciates this opportunity to discuss modernizing Standards of Identity (SOI) and the use of a horizontal approach to modernization. Learn More

USP Comment Letter: Submitted to FDA on Insulin Biosimilars (2019)

USP appreciates the opportunity to comment on “The Future of Insulin Biosimilars: Increasing Access and Facilitating the Efficient Development of Insulin Biosimilar and Interchangeable Products”. Learn More

USP Comment Letter: Submitted to FDA ‘Standards Development and the Use of Standards in Regulatory Submissions Reviewed in the Center for Biologics Evaluation and Research; Guidance for Industry (2019)

USP appreciates the opportunity to comment on the Food and Drug Administration’s (FDA or the Agency) final guidance, “Standards Development and the Use of Standards in Regulatory Submissions Reviewed… Learn More

USP Comment Letter: Submitted to FDA on Nonproprietary Naming of Biological Products: Update (2019)

USP appreciates the opportunity to comment on the Food and Drug Administration’s (FDA) draft guidance, “Nonproprietary Naming of Biological Products: Update.” Learn More

USP Sign-On Letter: Submitted to FDA In Support of Modernizing Policies for Dietary Supplements (2019)

USP supported the Food and Drug Administration's (FDA's) announcement that it will modernize policies to help ensure the availability of safe, well-manufactured, and appropriately labeled… Learn More

USP and Public Policy

Refine Your Search

Document Classification

Topics